DrugPatentWatch Database Preview
Patent: 6,462,017
» See Plans and Pricing
Summary for Patent: 6,462,017
| Title: | Method of reducing side effects of chemotherapy in cancer patients |
| Abstract: | A method for reducing the severity of chemotherapy side effects in cancer patients by administering thymosin .alpha..sub.1 in conjunction with the administration of a chemotherapy agent to the patient. As a result of the reduction of post-chemotherapy side effects, patients experience an increase in the quality of life. |
| Inventor(s): | Rudolph; Alfred R. (Los Altos Hills, CA), Tam; Vincent Chung-Ying (Hong Kong, HK), Quan; Maggie Jie (Shanghai, CN) |
| Assignee: | SciClone Pharmaceuticals, Inc. (San Mateo, CA) |
| Application Number: | 09/561,917 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,462,017
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | SciClone Pharmaceuticals, Inc. (San Mateo, CA) | 2039-02-26 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | SciClone Pharmaceuticals, Inc. (San Mateo, CA) | 2039-02-26 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | SciClone Pharmaceuticals, Inc. (San Mateo, CA) | 2039-02-26 | RX | Orphan | search |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | SciClone Pharmaceuticals, Inc. (San Mateo, CA) | 2039-02-26 | RX | Orphan | search |
| Eisai Inc | ONTAK | denileukin diftitox | VIAL | 103767 | 001 | 1999-02-05 | Start Trial | SciClone Pharmaceuticals, Inc. (San Mateo, CA) | 2039-02-26 | RX | Orphan | search |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | Start Trial | SciClone Pharmaceuticals, Inc. (San Mateo, CA) | 2039-02-26 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | SciClone Pharmaceuticals, Inc. (San Mateo, CA) | 2039-02-26 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 6,462,017
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 0182949 | Start Trial |
| Japan | 2004501870 | Start Trial |
| Hong Kong | 1060280 | Start Trial |
| European Patent Office | 1357935 | Start Trial |
| Germany | 60125417 | Start Trial |
| China | 100441221 | Start Trial |
| China | 1529614 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
